Cyclanoline Reverses Cisplatin Resistance in Bladder Cancer Cells by Inhibiting the JAK2/STAT3 Pathway
Cyc reverses cisplatin resistance <i>via</i> JAK/STAT3 inhibition in bladder cancer, offering a potential clinical strategy to enhance cisplatin efficacy in treating bladder cancer.
Authors
- Xianghui Kong (ORCID: https://orcid.org/0000-0003-3132-4019)
- Linjin Li
- Feng Wang (ORCID: https://orcid.org/0000-0003-2316-289X)
- Chengpeng Li (ORCID: https://orcid.org/0000-0001-6751-2770)
- R. Ye
- Wu Chen
- Feilong Miao
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2024-08-12
- DOI
- https://doi.org/10.2174/0118715206304668240729093158
- Citations
- 1
- Primary Topic
- Genomics, phytochemicals, and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 0.23